Program Description
The use of immune checkpoint inhibitors (ICIs) in cancer care has impacted treatment guidelines for many malignancies including renal cell carcinoma and melanoma. ICIs currently have approval as monotherapy and also in combination with targeted therapies, allowing for improved patient outcomes. Both ICIs and targeted therapies are associated with unique adverse effect profiles, and pharmacists are positioned to assist proactively in patients receiving these therapies. This activity will explain the role of ICIs and targeted therapy combinations across tumor types and will emphasize pearls for health-system pharmacists to optimally provide patient care.
Target Audience: Health-system pharmacists, oncology pharmacists, specialty pharmacists
Type of Activity: Application
Release date: March 1, 2022
Expiration date: May 1, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the role of immune checkpoint inhibitor (ICI)-targeted therapy combinations across malignancies
- Apply knowledge of ICI-targeted therapy combinations to treatment selection in patients with cancer
- Identify best practices for managing adverse effects associated with ICI-targeted therapy combinations
Jacob K. Kettle, PharmD, BCOP
Pharmacy Manager
Ellis Fischel Cancer Center
Department of Pharmacy
University of Missouri Health Care
Columbia, Missouri
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-044-L01-P. The activity is available for CE credit through May 1, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Jacob K. Kettle, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Speakers Bureau: Genentech, Merck & Co, Amgen, Lilly, DSI
Consultant: Pfizer, Lilly
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Meg Taylor, PharmD, CPP; Liz Rauh; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms